Tvardi Therapeutics Q3 net loss widens 11% to $6.12 million

PUBT · 2d ago
Tvardi Therapeutics Q3 net loss widens 11% to $6.12 million
  • Tvardi Therapeutics’ third-quarter 2026 net loss widened 11% year over year to $6.12 million.
  • Research and development expenses rose 24% to $4.47 million, driven primarily by higher TTI-101 clinical costs.
  • Cash and cash equivalents totaled $22.3 million at September 30, sufficient to fund planned operations into the third quarter of 2027.
  • Topline data from the Phase 1b/2 TTI-101 liver cancer study are expected early in the first quarter of 2027.
  • A TTI-109 ulcerative colitis trial is planned for 2027, subject to additional funding and investigational new drug application clearance.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tvardi Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611130700PRIMZONEFULLFEED9876971) on November 13, 2026, and is solely responsible for the information contained therein.